Following SABCS 2023, Carey K. Anders, MD, reviews recent updates from the KATHERINE and APHINITY clinical trials in HER2+ breast cancer.
Pembrolizumab Maintenance Yields Enduring Responses in HER2– Breast Cancer
Further research may validate identified biomarkers and refine patient selection criteria for pembrolizumab therapy in breast cancer.
Managing CDK4/6 Inhibitor, ADC Toxicity in Metastatic Breast Cancer
Sarah Donahue, MPH, NP, speaks to the importance of communicating potential adverse effects associated with treatments such as CDK4/6 inhibitors to patients with breast cancer.
7-Gene Predictive Biosignature Helps Predict Ipsilateral Breast Cancer Recurrence
DCISionRT is a risk-assessment test for patients designed to predict RT benefit and develop their recurrence risk after surgery alone or with radiation.
HER2CLIMB-02 Trial Shows ‘Interesting Data’ in HER2+ Breast Cancer
Tucatinib plus trastuzumab emtansine shows a progression-free survival improvement in HER2-positive breast cancer in the phase 3 HER2CLIMB-02 trial, says Sara A. Hurvitz, MD, FACP.
70 Navigating Lymphedema: The Impact of Indocyanine Green Lymphography (ICG_L) on Personalized Therapy Outcomes in Patients With Breast Cancer (BC)
Neoadjuvant/Adjuvant Pembrolizumab Regimens Lower RCB in ER+ Breast Cancer
The latest KEYNOTE-756 data highlight the surgical outcomes of patients with high-risk early-stage estrogen receptor–positive breast cancer.